ANIP - NASDAQ
ANI Pharmaceuticals, Inc.
$75.23
-1.9%ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
At a Glance
Live SnapshotANI Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Effective Tax Rate
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
ANI Pharmaceuticals, Inc. Income Statement
ANIP • NASDAQ
| ANI Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
883.4M | 614.4M | 486.8M | 316.4M | 216.1M | 208.5M | 206.5M | 201.6M | 176.8M | 128.6M | 76.3M | 56M | 30.1M | 2.3M | 435.2K | 2.5M | 1.3M | 3.8M | 493.1K | 14.4M | |
GROSS PROFIT | ||||||||||||||||||||
(432.7M) | (250.2M) | (181.5M) | (138.8M) | (100.6M) | (87.2M) | (63.2M) | (73M) | (79M) | (48.8M) | (12.7M) | (11.5M) | (10M) | (9.2M) | (50K) | (268.8K) | (0.0) | (0.0) | (0.0) | (0.0) | |
450.6M | 364.2M | 305.3M | 177.6M | 115.5M | 121.3M | 143.4M | 128.6M | 97.8M | 79.8M | 63.6M | 44.5M | 20.1M | -6.9M | 385.2K | 2.2M | 1.3M | 3.8M | 493.1K | 14.4M | |
OPERATING INCOME | ||||||||||||||||||||
(369.4M) | (363.6M) | (258.3M) | (212.9M) | (155.3M) | (137.3M) | (127M) | (93.2M) | (68.6M) | (53.1M) | (30.9M) | (24.5M) | (19.2M) | (25.5M) | (51.3M) | (45.8M) | (39.7M) | (21.8M) | (9.2M) | (11M) | |
(317.7M) | (249.6M) | (161.7M) | (124M) | (84.3M) | (65M) | (55.8M) | (44.1M) | (31.6M) | (27.8M) | (21.2M) | (17.9M) | (16.4M) | (8.2M) | (7M) | (5.9M) | (5.7M) | (6M) | (4.3M) | (7M) | |
(51.7M) | (44.6M) | (34.3M) | (22.3M) | (11.4M) | (16M) | (19.8M) | (15.4M) | (9.1M) | (2.9M) | (2.9M) | (2.7M) | (1.7M) | (16.9M) | (44.2M) | (39.7M) | (13.7M) | (15.8M) | (4.8M) | (3.9M) | |
81.2M | 584K | 47M | -35.3M | -39.8M | -16M | 16.4M | 35.4M | 28.3M | 20.1M | 32.7M | 20M | 898K | -23.2M | -50.9M | -43.6M | -38.4M | -18M | -8.7M | 3.4M | |
PRE-TAX INCOME | ||||||||||||||||||||
(20.1M) | (17.6M) | (26.9M) | (28.1M) | (11.9M) | (9.5M) | (13M) | (14.8M) | (12M) | (11.3M) | (11M) | (787K) | (467K) | (348K) | (681.6K) | (688.1K) | (147K) | (0.0) | (0.0) | (0.0) | |
-20.1M | -17.6M | -26.9M | -28.1M | -11.9M | -9.5M | -13M | -14.8M | -12M | -11.3M | -11M | -787K | -467K | -339.5K | -673.2K | -675.4K | -135.4K | 588.5K | 1.1M | 428.3K | |
(0.0) | (69.4M) | (62.3M) | (66.5M) | (59.7M) | (56.3M) | (51.4M) | -550K | (55K) | -74K | (41K) | (160K) | -305K | (353.9K) | (148.2K) | (168K) | (20.3M) | (43.1K) | (89.8K) | (117.8K) | |
14.6M | -22.8M | -27.1M | -27.4M | -16.3M | -9.9M | -13.2M | -15.3M | -12M | -11.4M | -11M | -627K | -772K | -5.6M | -681.7K | -2.6M | -9.1M | -17.4B | -7.6B | -1.1M | |
95.8M | -22.2M | 19.9M | -62.7M | -56.1M | -26M | 3.2M | 20.1M | 16.3M | 8.7M | 21.7M | 19.4M | 126K | -27.8M | -51.6B | -46.2B | -47.5B | -17.4B | -7.6B | 2.8B | |
NET INCOME | ||||||||||||||||||||
(17.5M) | -3.7M | (1.1M) | -14.8M | -13.5M | -3.4M | -2.9M | (4.6M) | (17.4M) | (4.7M) | (6.4M) | -9.4M | (20K) | -121.8K | (681.7K) | (2.6M) | (9.1M) | -17.4B | -7.6B | (648.5K) | |
78.3M | -18.5M | 18.8M | -47.9M | -42.6M | -22.5M | 6.1M | 15.5M | -1.1M | 3.9M | 15.4M | 28.7M | 301K | -27.7M | -51.6M | -46.2M | -47.5M | -17.4M | -7.6M | 2.8M |
SEC Filings
ANIP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 09, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 |
Related Guides
Continue your ANIP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.